The global wearable medical devices market is expected to surpass $29 billion by 2026, according to a report from Transparency Market Research (TMR), expanding at a projected compound annual growth rate (CAGR) of more than 17% over the next seven years.
The CDC’s most recent Health, United States report, released this April, reveals the extent to which racial and ethnic disparities in the U.S. affect cardiovascular care and rates of heart disease in the country.
The cardiology division at Columbia University’s Vagelos College of Physicians and Surgeons received a donation of $32.5 million this month—a gift the program’s leaders say will go toward patient care, research and education.
Pharmacy closures across the U.S. are driving significant declines in medication adherence among Americans, a recent study has found, especially those who are older and live in neighborhoods with low accessibility.
Three physicians published an editorial in Stroke proposing that tertiary healthcare centers in cities be held to stricter standards for performing endovascular thrombectomy (EVT) than their rural counterparts.
Several professional medical societies have now weighed in on a bill introduced to Congress on April 9 which seeks to prevent physicians from self-referring Medicare patients to in-office “ancillary services” including advanced imaging, anatomic pathology, radiation therapy and physical therapy.
The FDA’s decision to mandate labeling of added sugar content on packaged foods and beverages is estimated to prevent nearly 1 million cases of diabetes and cardiovascular disease over the next 20 years and save the U.S. $31 billion in net healthcare costs over that timeframe.
An April 2 story in the New York Times highlighted a potentially dangerous insurance coverage gap faced by heart transplant patients and recipients of other organs—the immunosuppressive drugs they need to prevent organ rejection sometimes aren’t covered by Medicare if they received the transplants before enrolling in the program.
French drugmaker Sanofi announced on April 10 a plan to lower its insulin prices to $99 per month for some U.S. patients, beginning in June. The announcement came amid a series of congressional hearings about drug costs and was met with questions about why this move and other recent cost-cutting measures took so long.